Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Multiple Myeloma 3Recurrence 1Myeloproliferative Disorders 1Lymphoma 1Leukemia 1Hematologic Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

fludarabine phosphate 55Cyclophosphamide 49Peripheral Blood Stem Cell Transplantation 47Mycophenolic Acid 40Tacrolimus 38Whole-Body Irradiation 32Busulfan 27Cyclosporine 25Antilymphocyte Serum 25Methotrexate 21Filgrastim 21fludarabine 19Melphalan 19Radiotherapy 14Methylprednisolone 13Sirolimus 11Flow Cytometry 10Etoposide 10Alemtuzumab 10Cord Blood Stem Cell Transplantation 9Rituximab 8Psychiatric Rehabilitation 8Granulocyte Colony-Stimulating Factor 8Therapeutics 7Polymerase Chain Reaction 7thymoglobulin 6sargramostim 5Prednisone 5Ondansetron 4Immunologic Techniques 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myeloproliferative Disorders × darinaparsin × Plasma cell × Clear all
NCT00592046 2012-07-19

A Phase I Trial of ZIO-101 in Hematologic Cancers

Alaunos Therapeutics

Phase 1 Completed
12 enrolled
Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Refractory, with Excess of Blasts, Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Disorders, Recurrence, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡